HURA
TuHURA BiosciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case assumes successful clinical progress or clear, non-dilutive financing that materially de-risks lead programs and drives re-rating into microcap growth multiples; modelled as ~+40% from the anchor given limited float and binary upside.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Bear case assumes dilutive financing or negative trial news leading to sustained discount; modeled as ~-30% from anchor reflecting typical small-biotech downside on dilution or setbacks.
Momentum
98
Value
42
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.26 · Bull $2.87 · Bear $1.44
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum98 · Δ7d -
Value42 · Δ7d +0.1
Sentiment52 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
98
34% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
52
33% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 98.1 / Value 41.9 / Sentiment 52.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$142.65M
Beta
0.12
Shares Out
60.72M
P/E (TTM) · Derived
-1.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.64
Rev YoY
-
EPS YoY
+89.8%
Gross Margin
-
Op Margin
-
Net Debt
-$12.66M
Current Ratio
0.40
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology